Open AccessRapid Review
Author(s) -
Eli D. Ehrenpreis,
David H. Kruchko
Publication year - 2020
Publication title -
journal of clinical gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.141
H-Index - 112
eISSN - 1539-2031
pISSN - 0192-0790
DOI - 10.1097/mcg.0000000000001371
Subject(s) - medicine , nonsteroidal , ibuprofen , covid-19 , inflammatory bowel disease , anti inflammatory , inflammatory bowel diseases , intensive care medicine , disease , pandemic , pharmacology , infectious disease (medical specialty) , pathology , outbreak
In the current COVID-19 pandemic, there has been concern regarding the use of ibuprofen and other nonsteroidal anti-inflammatory agents by COVID-19 infected patients. Aminosalicylates (5-ASAs) are structurally similar and have anti-inflammatory functions that resemble those of nonsteroidal anti-inflammatory agents. Since 5-ASAs are a mainstay treatment for inflammatory bowel disease, the authors review the pharmacology of both classes of drugs and discuss the potential relevance of 5-ASAs in the ongoing discussion of medication use in patients infected with COVID-19.